OCWP
JBIO

Owl Creek Wealth Partners’s Jade Biosciences JBIO Stock Holding History

Owl Creek Wealth Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156 Hold
7
– – ﹤0.01% 1284
2026
Q1 		$99 Buy
+7
New +$101 ﹤0.01% 1235

Other funds holding JBIO

JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Owl Creek Wealth Partners's JBIO Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Jade Biosciences (JBIO) position steady in Q2 2026 at 7 shares worth $156. The position accounts for ﹤0.01% of the portfolio, ranked #1284.

Owl Creek Wealth Partners first reported a position in JBIO in Q1 2026 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Owl Creek Wealth Partners held 7 shares of Jade Biosciences worth $156 as of Q2 2026.
  • Owl Creek Wealth Partners left its Jade Biosciences share count unchanged in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1284 holding.
  • Owl Creek Wealth Partners first reported a position in Jade Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 141 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.